SCAI President James Hermiller, Jr., MD, explains the need for more innovative radiation protection systems in the cath lab.

A team of pediatric specialists worked closely with representative from Medtronic to develop the new pacemakers. Overall, the tiny devices—approximately one-quarter the size of a traditional pacemaker—were found to be both safe and effective. They are still under development.

One of the cardiologists involved in the procedures said they represent "a significant leap forward in structural heart intervention."

The valve's sutureless, collapsible frame was built to simplify implantation and help patients recover faster following surgery. This updated version features laser-cut details and was shaped using a zero-pressure fixation process.

The new Self-Centering Guide Catheter was designed to help care teams with the retrograde crossing of the aortic valve during TAVR. Researchers evaluated the safety and effectiveness of the catheter, sharing their experience in JACC: Cardiovascular Interventions.

Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.

The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients.

Pi-Cardia, an Israeli medtech company, describes ShortCut as the “world’s first dedicated leaflet modification device."